RxDoctor Payments Data

Timothy Muchayi, MD

Nephrology · Miami, FLNPI 1073743902

Payments from drug & device makers

$3,373in general payments, 2019–2025

Across 143 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$499
  • Vifor Pharma, Inc.$404
  • AstraZeneca$388
  • Calliditas Therapeutics US Inc.$379
  • Otsuka America Pharmaceutical, Inc.$232
  • Amgen$218
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,35399%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,373 in reported general payments places this provider in the 60th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$270,029
Medicare patients
500
Services billed
1,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol146$163,565
VeltassaPatiromer Calcium Sorbitex59$80,977
KerendiaFinerenone49$74,386
LokelmaSodium Zirconium Cyclosilicate33$42,457
JardianceEmpagliflozin31$42,219
VelphoroSucroferric Oxyhydroxide16$28,946
ProcritEpoetin Alfa26$9,033
Cinacalcet Hcl17$6,542
RetacritEpoetin Alfa-Epbx13$3,652
Sevelamer Carbonate32$3,160
Nifedipine ErNifedipine61$2,318
Torsemide125$2,169
Clonidine14$1,740
Famotidine86$1,576
Losartan Potassium121$857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$388$206,023179 claims
BayerKerendia$499$74,38649 claims
Boehringer IngelheimJardiance$125$42,21931 claims
Fresenius USA Marketing, Inc.Velphoro$85$28,94616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 756 nephrology providers in Florida.

Other nephrology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →